英飛拓(002528.SZ):掛牌轉讓的上海偉視清60%股權由芯江科技以1842.26萬元摘得
格隆匯12月27日丨英飛拓(002528.SZ)公佈,為順應公司戰略發展,優化資產結構,維護上市公司股東權益,公司於2021年12月20日在淘寶網資產競價網絡平台上公開掛牌轉讓控股子公司上海偉視清數字技術有限公司(“上海偉視清”)60%股權。
以2021年8月31日為基準日,資產評估機構及專業審計機構出具的評估報吿及資產核資專項審計報吿為定價參考依據,確定上海偉視清60%股權的掛牌底價為人民幣1842.264萬元。
截至目前,公開掛牌交易程序已完成,根據掛牌結果,交易對方確定為上海芯江科技有限公司(“芯江科技”),交易價格為人民幣1842.264萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.